![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » EC GRANTS ORPHAN-DRUG DESIGNATION TO NEXAVAR
EC GRANTS ORPHAN-DRUG DESIGNATION TO NEXAVAR
April 18, 2006
Bayer Pharmaceuticals and Onyx Pharmaceuticals have announced that Nexavar (sorafenib) has been granted orphan-drug status for the treatment of hepatocellular carcinoma by the European Commission (EC). This designation is based on a recommendation from the Committee for Orphan Medicinal Products of the European Medicines Agency.
A Phase III trial of Nexavar administered as a single agent is ongoing. The study is designed to measure differences in overall survival, time-to-symptom progression and time-to-tumor progression of Nexavar versus placebo in liver cancer patients. A randomized Phase II trial for liver cancer patients to evaluate the efficacy of Nexavar in combination with the chemotherapeutic agent doxorubicin is also ongoing.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct